UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

Clinical trial NCT06590961 · RECRUITING

Trial details

NCT number: NCT06590961
Sponsor: Ubix Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsed/Refractory B-cell Malignancies

Start date: 2025-02-20
Primary completion: 2027-08-01
Enrollment: 94

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.